EDISON EQUITY RESEARCH: SYMBIO PHARMACEUTICALS

EDISON EQUITY RESEARCH: SYMBIO PHARMACEUTICALS - WITH EXPERIENCE COMES CONFIDENCE

Three steps forward, one step back. With the December filing of three supplemental NDAs for Treakisym, SymBio is demonstrating it is willing to move ahead with its strategic plans despite Astellas’s decision to withdraw its long-delayed EU application for Treakisym in first-line iNHL. Separately, Baxalta announced on 3 March that it would discontinue its development and licensing agreement with Onconova for rigosertib as of August. Onconova is in discussions with Baxalta; however, it is not clear whether Baxalta will help Onconova obtain alternate funding to complete the trial. Issues with SymBio’s partners may have an impact on the timeframes for both rigosertib and the Treakisym label expansion approvals.

SymBio Pharmaceuticals is a Japanese specialty pharma company with a focus on oncology, haematology and pain management. Treakisym was in-licensed from Astellas in 2005. Rigosertib was in-licensed from Onconova and IONSYS was in-licensed from The Medicines Company.

To view our full report, please click here 

Click here to view all of Edison Investment Research's published reports